Drug provides relief to those with overactive bladder

The FDA recently approved trospium (Sanctura, Indevus Pharmaceuticals/Odyssey Pharmaceuticals) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. The product launch of trospium is expected to take place during the third quarter of 2004.